Questions and answers
Straight answers.
Each answer is marked as a fact about Reedley today, something we intend, or a question we cannot yet answer.
Today a factIntended not yet in placeNot yet known unresolved
About Reedley
What is Reedley?
TodayReedley is clinical workflow software being built for UK general practice. It is designed to read clinical correspondence, results and monitoring signals, show the evidence behind each item of work, propose actions for people to decide on, and confirm that work was completed once approved access to clinical systems exists. Today it runs on synthetic data only.
TodayIt is in development and has been built and tested on synthetic data only.
Who is it intended for?
IntendedGP practices and primary care networks in the UK: clinical pharmacists, GPs, practice managers, administrative and workflow teams, and network leads.
Is it available now?
TodayNo. Reedley is not available for use with real patients and no practice uses it today.
IntendedWe are recruiting a small number of practices and networks for synthetic walkthroughs, followed — only with the right approvals — by governed evaluation.
Not yet knownWe do not yet know when it will be generally available. That depends on clinical safety work, supplier integration approvals and what pilots show.
Clinical responsibility
Does it replace clinicians?
TodayNo. Reedley is designed to remove reading, checking and chasing around clinical decisions, not the decisions themselves. Every proposal needs a named person to accept, edit or reject it.
Does it make clinical decisions?
TodayNo. It does not diagnose, interpret results, prescribe or act without a person. Conditional wording in letters is flagged for a clinician, never treated as an instruction.
Not yet knownWhether any feature falls within medical-device regulation has not yet been assessed by a specialist. Features that could shape prescribing will not be used with real patients until that assessment is done; on this site they are shown on synthetic data with their status.
Can it prescribe medication?
TodayNo. Reedley does not prescribe and does not add, stop or change medicines in the clinical record. Not writing to the medication record is Reedley’s design. Whether any supplier route would permit it is not established on current evidence, and no application has been made.
Is Reedley a medical device?
Not yet knownNot yet determined. Whether software is a medical device depends on its intended purpose and how it is described. Reedley has not had a specialist regulatory assessment, so we make no claim either way.
IntendedA regulatory specialist will assess each feature against MHRA guidance before any clinical use. If any part qualifies, it will follow the required UK conformity route before it is used, and the outcome will be published in the assurance register.
What happens if the AI makes an error?
TodayEvery finding links to the exact source passage so the reviewer can check it. Errors such as incomplete or incorrect extraction are recorded as hazards in the draft hazard log.
IntendedBefore any real use, a Clinical Safety Officer will own the hazard log, and practices will have a route to report safety concerns and pause affected functionality.
Not yet knownExtraction accuracy is not established: one model run, on synthetic development documents only.
Clinical systems
Does it connect to EMIS Web?
TodayNot today. Reedley is designed around EMIS Web workflows, but no integration exists, none is claimed, and no supplier has approved or partnered with Reedley.
IntendedWe intend to pursue the published integration routes, such as IM1 pairing, and will report each step on the integration page.
Does it connect to SystmOne?
TodayNot today. The same applies as for EMIS Web: designed for SystmOne workflows, with no integration existing or claimed.
Data and security
Does it use patient data to train AI?
TodayReedley does not currently process any real patient data.
IntendedOur intended position is that patient data will not be used to train models. This will be confirmed in contracts with any model provider and in each practice’s data processing agreement before any pilot.
Where would clinical data be processed?
IntendedWe intend clinical data to be processed in the UK, with any exception listed and agreed with the practice.
Not yet knownNo hosting or model provider has been contracted for clinical use yet, so we cannot name them.
How is information protected?
TodayIn the development build: practice-level separation of data, role-based access with a record of every access attempt, and append-only audit history — tested on synthetic data. On the branch awaiting review (since 14 November), a GP, pharmacist or nurse sees safeguarding-classified content with a flag and an audited view by default; non-clinical roles need an explicit grant, and a practice can withhold it from clinicians only by recording a rationale. Not reviewed by a Clinical Safety Officer, safeguarding lead or information-governance lead. These rules are enforced only by Reedley’s own screens and the build has no authenticated user, so none of them is a security boundary yet.
IntendedBefore any real data: encryption, strong authentication, DSPT, Cyber Essentials Plus and independent penetration testing.
Pilots and evaluation
What does a pilot involve?
IntendedA conversation, then synthetic walkthroughs, then structured feedback. Governed evaluation with real data happens only with a CSO-approved safety case (DCB0129), your DCB0160 assessment, an MHRA device determination, DSPT, a DPIA, a data processing agreement and supplier approvals in place.
How is the product evaluated?
TodayOn synthetic data today: a regression suite, a locked holdout set, and one model-in-the-loop run on the development set (13 November 2026) against provisional thresholds with no clinical weight. The suite is designed to report false negatives and false positives separately; no accuracy figure is claimed.
IntendedWith practices: timed walkthrough tasks and interviews, then governed pilots with agreed measures. Synthetic results will never be presented as real-world performance.
How can an organisation express interest?
TodayRegister interest, or apply in detail, on the pilot interest page, or contact us. No pilot is running yet. Please do not include any patient information.
Questions buyers ask
What will it cost?
TodayPricing has not been set. Pilot participation would be agreed individually; we will not ask a practice to pay for something that is not ready.
Who is building Reedley?
TodayReedley is at an early stage and is currently founder-led. Its founder, Salim Miah MPharm, is a UK-qualified pharmacist and independent prescriber who has worked across community pharmacy, hospital and general practice.
IntendedAs Reedley grows, clinical safety, engineering and information governance roles will be filled by suitably qualified people, and we will name them here.
How much of our team’s time does a pilot take?
TodayStage 1 is about an hour; registering interest takes about a minute and applying about five minutes.
Not yet knownStages 2–4 are agreed with you in the conversation; we will not guess.
Not answered here?
Ask us directly. If we do not know yet, we will say so.